KYE Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesDrug Stores & Pharmacies · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2233 Argentia Rd. Suites 302 & 302A, Mis...Website
www.kyepharma.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About KYE Pharmaceuticals
Kye Pharmaceuticals is dedicated to addressing the challenges of the pharmaceutical environment in Canada, focusing on the registration and commercialization of innovative medicines. The company aims to fulfill clinically significant unmet medical needs through its growing portfolio of therapeutics. Kye actively partners with other organizations to acquire or license important medicines for the Canadian market. Their commitment extends to healthcare professionals and patients, ensuring a positive impact across multiple therapeutic areas.Explore more
KYE Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is KYE Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
KYE Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once KYE Pharmaceuticals has new funding data
Earning: See what the market has to say on KYE Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if KYE Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when KYE Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at KYE Pharmaceuticals
Click to see if KYE Pharmaceuticals had a recent Job posting/layoffs
Check if KYE Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at KYE Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to KYE Pharmaceuticals
Compare insights from companies similar to KYE Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
KYE Pharmaceuticals is experiencing very low activity levels compared to other companies in the Retail sector.
What does this means?
KYE Pharmaceuticals is drawing exceptional interest within the Retail industry, suggesting notable developments or strong market momentum, learn more about KYE Pharmaceuticals.
KYE Pharmaceuticals Tech Stack
A closer look at the technologies used by KYE Pharmaceuticals
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
KYE Pharmaceuticals News & Media
Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada
Prevalence of Autism Spectrum Disorder (ASD) among children and youth aged 1 to 17 years, is about 2% (1 in 50) and is equivalent to about 150,000 cases in Canada in 2025 [1, 2]. Smith-Magenis syndrome (SMS) is a very rare (1:15,000 to 1:25,000 births) genetic neurodevelopmental disorder...Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for the disease in Canada. The Canadian Neuromuscular Disease registry estimates that there are more than 800 boys and young men living with DMD in Canada and coping with its debilitating symptoms.Health Canada Approves AGAMREE® (vamorolone) as the First Treatment for Duchenne Muscular Dystrophy in Canada
MISSISSAUGA, ON, Oct. 2, 2025 /PRNewswire/ - Kye Pharmaceuticals ("Kye") announced today that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in boys age 4 and older.1 This approval – granted under Health Canada's Priority Review...Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticostero
Read more news
Top Drug Stores & Pharmacies Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding KYE Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Kye Pharmaceuticals is dedicated to addressing the challenges of the pharmaceutical environment in Canada, focusing on the registration and commercialization of innovative medicines. The company aims to fulfill clinically significant unmet medical needs through its growing portfolio of therapeutics. Kye actively partners with other organizations to... Read More
